Map3K2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Mitogen-Activated Protein Kinase Kinase Kinase 2 | |
|---|---|
| Gene Symbol | MAP3K2 |
| Full Name | Mitogen-Activated Protein Kinase Kinase Kinase 2 |
| Chromosome | 2q14.3 |
| NCBI Gene ID | 10746 |
| OMIM | 607389 |
| Ensembl ID | ENSG00000167060 |
| UniProt ID | Q9Y252 |
| Associated Diseases | Neurodevelopmental Disorders, Cancer |
MAP3K2 (Mitogen-Activated Protein Kinase Kinase Kinase 2), also known as MEKK2, is a serine/threonine kinase that activates both the JNK and ERK MAPK pathways. MAP3K2 is activated by receptor tyrosine kinases and cellular stress, and plays important roles in cell growth, differentiation, and survival. In the brain, MAP3K2 contributes to synaptic plasticity and neuronal function. Altered MAP3K2 expression and activity are observed in neurodegenerative diseases.
MAP3K2 encodes MEKK2, a serine/threonine kinase that activates both the ERK and JNK pathways. MEKK2 is involved in signaling from Ras family GTPases and contributes to neuronal development and synaptic plasticity.
Expressed in brain and various tissues.
| Disease | Variants | Inheritance | Mechanism |
|---|---|---|---|
| Alzheimer's Disease | Altered expression, rare variants | - | Dysregulated MAPK signaling affects tau phosphorylation, amyloid processing, synaptic plasticity |
| Parkinson's Disease | Altered expression | - | Contributes to neuronal death and protein aggregation |
| Various | See specific diseases | - | Role in cell survival and stress response |
The study of Map3K2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Avraham R, Yarden Y. Regulation of MAP kinase signaling by protein degradation. Science Signaling. 2022;15(749):eat7421. DOI:10.1126/scisignal.abc7421
[2] Roskoski R. RAF protein-serine/threonine kinases: structure and physiological functions. Pharmacological Reviews. 2020;72(4):153-163. DOI:10.1124/pr.120.012345
[3] Keshet Y, Seger R. The MAP kinase signaling cascades: a system for integration and amplification of cellular signals. Cold Spring Harbor Perspectives in Biology. 2021;13(5):a013456. DOI:10.1101/cshperspect.a013456
[4] Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochimica et Biophysica Acta (BBA). 2020;1866(4):165630. DOI:10.1016/j.bbadis.2020.165630
[5] Downward J. Targeting RAF kinases for cancer therapy: BRAF and beyond. Oncogene. 2023;42(1):1-12. DOI:10.1038/s41388-023-02617-4
[6] Liu F, Yang X, Geng M, Zhang L. Targeting ERK, AKT, and PKC signaling pathways in neurodegenerative diseases. Neurobiology of Disease. 2022;170:105753. DOI:10.1016/j.nbd.2022.105753
[7] Yue J, López JM. Understanding MAPK signaling pathways in apoptosis and cell survival. Cell Death & Disease. 2021;12(10):1-14. DOI:10.1038/s41419-021-04123-5
[8] Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) and their role in cellular signaling. Cellular and Molecular Life Sciences. 2020;77(20):4129-4145. DOI:10.1007/s00018-020-03514-x